A detailed history of Exodus Point Capital Management, LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 318,394 shares of SNDX stock, worth $5.08 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
318,394
Previous 625,723 49.12%
Holding current value
$5.08 Million
Previous $12.8 Million 52.29%
% of portfolio
0.04%
Previous 0.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$17.93 - $24.81 $5.51 Million - $7.62 Million
-307,329 Reduced 49.12%
318,394 $6.13 Million
Q2 2024

Aug 13, 2024

BUY
$18.82 - $23.79 $6.39 Million - $8.07 Million
339,393 Added 118.53%
625,723 $12.8 Million
Q1 2024

May 14, 2024

BUY
$19.71 - $24.57 $2.57 Million - $3.21 Million
130,616 Added 83.88%
286,330 $6.82 Million
Q3 2023

Nov 09, 2023

SELL
$14.52 - $21.77 $726,058 - $1.09 Million
-50,004 Reduced 24.31%
155,714 $2.26 Million
Q2 2023

Aug 10, 2023

BUY
$19.35 - $22.31 $2.78 Million - $3.21 Million
143,845 Added 232.48%
205,718 $4.31 Million
Q1 2023

May 11, 2023

BUY
$20.66 - $28.98 $1.28 Million - $1.79 Million
61,873 New
61,873 $1.31 Million
Q3 2022

Nov 10, 2022

SELL
$18.51 - $24.79 $35,002 - $46,877
-1,891 Reduced 3.13%
58,466 $1.41 Million
Q2 2022

Aug 19, 2022

BUY
$13.64 - $19.48 $554,929 - $792,524
40,684 Added 206.8%
60,357 $1.16 Million
Q1 2022

May 13, 2022

BUY
$14.84 - $22.15 $291,947 - $435,756
19,673 New
19,673 $342,000
Q2 2021

Aug 16, 2021

SELL
$13.42 - $25.18 $139,017 - $260,839
-10,359 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$19.28 - $24.59 $199,721 - $254,727
10,359 New
10,359 $232,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $902M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.